IPOs and Secondaries

IPOs and Secondaries Articles

The United States may block Chinese investment in some companies, GE may sell one of its divisions, and other important headlines.
A dozen firms are scheduled to test the U.S. equity markets this week seeking $2.8 billion in new IPO capital.
This company is pioneering the future of medical cannabis research, cultivation, processing and distribution globally, and it intends to become a leader in the adult-use cannabis market in Canada...
Xiaomi had been looking forward to raising $10 billion in two IPOs, one in Hong Kong and one in Shanghai. But the Chinese smartphone maker has delayed its Shanghai offering while it sorts out a...
SurveyMonkey announced that its parent company, SVMK, has submitted a draft registration statement with the SEC for its initial public offering. This is a confidential filing.
Clinical-stage immuno-oncology company Forty Seven intends to price more than 6 million shares so that the entire offering is valued up to more than $123 million.
Seven years after being taken private by two private equity firms, BJ's Wholesale Club has filed terms for an IPO. The company plans to pay down debt with the the proceeds.
Neon Therapeutics filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. The company intends to price its 6.25 million shares in the...
Avalara filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. The company intends to price its 7.5 million shares in the range of $21...
U.S. Xpress Enterprises filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. The company expects to sell its 18.06 million shares...
The IPO trickle so far in June is surging this week. Seven companies are scheduled to tap the capital markets for $1.4 billion in new funding.
Clinical-stage immuno-oncology company Forty Seven has amended its filing with the SEC regarding its initial public offering.
Verrica Pharmaceuticals expects to price 5 million shares in the range that results in an initial public offering valued up to $92 million.
Deciphera Pharmaceuticals saw its shares took a breather early Tuesday after the firm announced a secondary offering.
June is off to a modest start with two IPOs on the calendar for the coming week. Combined the two firms are seeking to raise about $160 million in new capital.